Liquidia Corporation (LQDA)
Liquidia Corporation is a biopharmaceutical company listed on NASDAQ under the ticker LQDA. The company focuses on developing, manufacturing, and commercializing therapies for rare cardiopulmonary diseases in the United States. Its lead product candidate is YUTREPIA, an inhaled dry powder formulation of treprostinil being developed for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia also markets Remodulin, a treprostinil injection delivered by continuous intravenous or subcutaneous infusion, and is advancing L606, an investigational liposomal treprostinil product in phase III clinical development for the same disease areas. In addition, the company’s PRINT technology is designed to produce uniform drug particles with controlled size, shape, and composition. Liquidia was founded in 2004 and is based in Morrisville, North Carolina.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-LQDA
|
$57.43
|
0.0% Upside
|
Fair
|
$63.88
|
11.3% Upside
|
Fair
|
Great
|
0.0%
|
March 18, 2027
|
8.4x
|
5.169 B
|
5.014 B
|
3.1%
|
73.0%
|
5.3
|
-309.1%
|